Wolff Stefani 4
4 · Rain Oncology Inc. · Filed Jan 26, 2024
Insider Transaction Report
Form 4
Wolff Stefani
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−35,000→ 0 totalExercise: $1.21→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−24,000→ 0 totalExercise: $15.91→ Common Stock (24,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−20,000→ 0 totalExercise: $2.44→ Common Stock (20,000 underlying)
Footnotes (1)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.